Related Experiment Video
Updated: Sep 25, 2026

Genotyping Single Nucleotide Polymorphisms in the Mitochondrial Genome by Pyrosequencing
Published on: February 10, 2023
Spasmodic dysphonia in a patient with the A to G transition at nucleotide 8344 in mitochondrial DNA
Ying Peng1, Roger Crumley, John M Ringman
1Department of Pediatrics, University of California at Irvine, Orange, California 92868, USA.
Abstract:
Dystonia has been described in various diseases affecting mitochondrial function but spasmodic dysphonia, a form of focal dystonia, has not. We present a patient with action myoclonus affecting the hands and arms who carried the most common mutation in mitochondrial DNA causing the myoclonic epilepsy and ragged red fibers (MERRF) syndrome (the A-->G substitution at nucleotide 8344 in the tRNA(Lys) gene). This patient also had spasmodic dysphonia that was responsive to treatment with intralaryngeal botulinum toxin.
Insights
Spasmodic dysphonia, a focal dystonia, was observed in a patient with myoclonic epilepsy and ragged red fibers (MERRF) syndrome. Treatment with botulinum toxin effectively improved the patient's spasmodic dysphonia.
Area of Science:
- Neurology
- Genetics
- Mitochondrial Diseases
Background:
- Dystonia is associated with mitochondrial dysfunction.
- Spasmodic dysphonia, a focal dystonia, has not been previously linked to mitochondrial diseases.
- Myoclonic epilepsy and ragged red fibers (MERRF) syndrome is caused by a common mitochondrial DNA mutation.
Observation:
- A patient presented with action myoclonus in the hands and arms.
- This patient carried the A8344G mutation in the mitochondrial tRNA(Lys) gene, causative of MERRF syndrome.
- The patient also exhibited spasmodic dysphonia.
Findings:
- The patient's spasmodic dysphonia responded positively to intralaryngeal botulinum toxin treatment.
- This case suggests a potential link between MERRF syndrome and spasmodic dysphonia.
- Mitochondrial dysfunction may contribute to focal dystonias like spasmodic dysphonia.
Implications:
- This finding expands the clinical spectrum of MERRF syndrome.
- It highlights the potential role of mitochondrial dysfunction in the pathophysiology of spasmodic dysphonia.
- Botulinum toxin is a viable treatment option for spasmodic dysphonia in patients with MERRF syndrome.
Related Concept Videos
Animal Mitochondrial Genetics
Translation
Translation
Point and Frameshift Mutations
ATP Synthase: Mechanism
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
